// App-Quantinova.ai

4189 : Omission of Methotrexate Doses Due to Toxicity Does Not Influence the Incidence of Gvhd, Relapse, or Survival

Researchers

Presenter

  • Housam Haddad

Principal Investigators

  • Edward A. Copelan

  • Brian T. Hill

  • Matt Kalaycio

  • Lisa Rybicki

  • Shawnda Tench

  • Melissa Yurch

  • Brian J. Bolwell

  • Rabi Hanna

  • Ronald Sobecks

  • Robert M Dean

  • Hien K. Duong

Medical Centers

  • Hematology/Oncology, Long Island Jewish Medical Center, Lake Success, NY, USA,

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Myeloid neoplasms

  • Graft-versus-host disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Primary plasma cell leukemia

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Mucositis

  • Lymphomas

Biomarkers

  • Hematocrit

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Cyclosporine eent

  • Methotrexate

  • Tacrolimus

  • Etoposide

  • Etoposide phosphate

  • Busulfan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved